Ninety-six AML patients in 1st CR were evaluated for peak CD34 þ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34 þ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34 þ cell peak p70 Â 10 9 /L (n ¼ 48); group B, those having a CD34 þ cell peak between 70 and 183 Â 10 9 /L (n ¼ 24); group C, those having a CD34 þ cell peak 4183 Â 10 9 /L (n ¼ 24). Irrespective of post-remission treatment received, group A had a disease free survival (DFS) of 73%, group B a DFS of 51% and group C of 30% (P ¼ 0.0003). In intermediate cytogenetic risk patients, those treated by autologous transplantation had a DFS of 68, 33 and 14% in the groups A, B and C, respectively, (P ¼ 0.01) whereas after allogeneic transplantation DFS was 87% in group A þ B vs 50% in group C (P ¼ 0.009). The peak of CD34 þ cells in PB, was an independent predictor for DFS in multivariate analysis.
Introduction
A CD34 þ cell count greater than 7 Â 10 6 /kg harvested in a single apheresis or a high percentage of CD34 þ cells in an apheretic harvest, has been reported to be a negative prognostic factor in AML patients in 1st remission. 1, 2 These data, however, still await confirmation. Further, it is not known if the prognostic value of CD34 þ cell mobilization can be overcome by allogeneic transplantation. Such information would be critical for planning different post-remission treatments.
Whereas, the degree of CD34 þ cell mobilization in peripheral blood (PB) is a prognostic factor in AML patients, measuring the peak level of CD34 þ cells present in PB during mobilization is likely to be a superior method for determining prognosis. In fact, the peak level of CD34 þ cells in PB is not influenced by some of the variables known to affect the number of CD34 þ cells harvested during apheresis, namely the volume of blood treated and the collection efficiency. 3 The peak level of CD34 þ cells in PB also has the advantage of providing data from an unselected and greater number of patients. In fact, the number of CD34 þ cells collected is a parameter that implicitly selects mobilized patients. This excludes at least 25% of AML patients in whom the process of mobilization fails, [4] [5] [6] and in whom no apheresis is attempted. For these reasons, we studied the prognostic significance of CD34 þ cell peak levels in PB after consolidation in a group of AML patients during first CR.
Our study revealed that determination of peak levels of CD34 þ cells allows for the identification of a subset of patients, with poor prognosis from within a group of patients classified as having an intermediate cytogenetic prognosis. The prognostic value of the CD34 þ cell peak in PB is higher in patients treated by autologous transplantation and less evident in those allotransplanted.
Patients and methods

Selection of patients
We studied patients affected by AML in 1st CR aged o65 years referred to us for post-remission treatment, with either autologous or allogeneic transplant. All patients were subjected to autologous PBSC mobilization, and apheretic harvest was used either as a source of hematopoietic stem cell (HSCs) for autologous transplant or as an autologous HSC back-up, if it was required after an allogeneic transplant.
We excluded patients affected by AML secondary to previous chemotherapy, or preceded by a diagnosis of myelodysplastic syndrome for more than 6 months. Patients with AML-FAB-M3 were also excluded.
Patients (n ¼ 101) were prospectively registered at the start of G-CSF-mobilizing therapy after administering the first consolidation cycle. In five patients, G-CSF was interrupted because of severe infections that arose during the aplastic phase (two pneumonia, three sepsis). The remaining patients (n ¼ 96) were, therefore, evaluated for the CD34 þ cell peak in PB.
All received a cytogenetic study at diagnosis, while we also looked for a molecular mutation involving FLT3 in 50 patients.
The inclusion period was from July 2000 to March 2010. Data were analyzed in September 2010 when median follow-up of surviving patients was 205 weeks (range 25-501).
The clinical features of patients included in the study and a comparison between groups identified by CD34 þ cell peak in PB are reported in Table 1 . No differences were found between groups except that group C (CD34 þ cell peak 4183 Â 10 9 /L) had a significantly lower percentage of good cytogenetic risk than the remaining patients (groups A þ B), P ¼ 0.05.
Study design
All patients were registered for this study at the start of G-CSF treatment, at day þ 15 after the beginning of their first cycle of consolidation therapy. During CD34 þ cell mobilization, daily counts of CD34 þ cells in PB were performed starting at a count of WBC 41.0 Â 10 9 /mL. The study was approved by the Institutional Review Board at our hospital, and patient consent to data collection was obtained. The peak number of CD34 þ cells in PB was used for the final analysis in September 2010, to divide patients into groups. Cut-offs to define groups were obtained from percentile distribution of CD34 þ cell peaks in PB: the 25th percentile of CD34 þ cell peak was 17 Â 10 9 /L; 50th percentile was 70 Â 10 9 /L; 75th percentile was 183 Â 10 9 /L. Disease free survival (DFS) in the four groups obtained were: 78, 69, 51 and 30%.
Since difference in DFS observed between patients in the first percentile group (CD34 þ cell peakp17 Â 10 9 /L ) and those having a CD34 þ cell peak of between 18 and 70 Â 10 9 /L was NS, these two groups were merged into one group (group A, 48 patients). The second group was made up of those with a peak of between 71 and 183 Â 10 9 /L (group B, 24 patients). The third group consisted of patients having a CD34 þ cell peak 4183 Â 10 9 /L (group C, 24 patients).
AML treatment and PBSC mobilization
Eighty-nine out of the 96 patients were treated according to the LAM GIMEMA 99P protocol: induction therapy was based on DNR 50 mg/m 2 for 3 days, Ara-C 100 mg/m 2 , continuous IV infusion (c.i.) for 10 days and etoposide 100 mg/m 2 for 5 days. Consolidation was DNR 50 mg/m 2 for 3 days and Ara-C 500 mg/m 2 q 12 h intravenously In the remaining seven patients, induction and consolidation were both 3 þ 7 type cycles, that is, DNR 50 mg/m 2 for 3 days plus Ara-C 100 mg/m 2 c.i. for 7 days. PBSC mobilization was obtained by administering G-CSF at a dose of 5 mcg/kg subcutaneously from day 15 after the start of the first consolidation chemotherapy to the end of PBSC apheresis, or until failure of CD34 þ cell mobilization was demonstrated (CD34 þ cells o10 Â 10 9 /L after day 28 with a WBC count 42 Â 10 6 /mL). CD34 þ cells in the PB and BM were enumerated using double-platform methods (ISHAGE protocol) with an EPICS XL (Beckman Coulter, Milan, Italy). 7 Throughout the entire period of the study, our laboratory participated in quality controls organized for CD34 þ cell determination (UKNEQAS Network, Sheffield, UK). Choice of post-remission treatment Decisions on post-remission treatment were based on recognized prognostic factors present at diagnosis such as cytogenetic alterations or FLT3 mutation. In the presence of a family HLA-identical donor, an allogeneic transplant was considered in all cases. The search for an unrelated donor was carried out for all patients having no sibling donor, if karyotype was classified as cytogenetically unfavorable or if a FLT3 mutation was found at diagnosis. All other patients were treated by Auto-SCT transplants. In patients having a poor PBSC collection, a BM harvest was attempted where the indications for autologous transplant were established.
Autologous transplantation
A total of 40 patients underwent an autologous transplant. The conditioning schedules before autologous transplants were BU-CY (n ¼ 33) or high dose melphalan (n ¼ 7). The HSC source for autologous transplant was marrow (n ¼ 16), PBSC (n ¼ 22) and in two cases marrow þ PBSC. In the group of poor mobilizer patients (n ¼ 24), defined by a CD34 þ cell peak o20 Â 10 9 /L, 9/24 were selected for autologous transplant. All nine of these patients underwent a BM harvest, whereas in 1/9 the marrow harvest cell yield was judged to be insufficient, in all other cases it was considered adequate and autologous transplantation was successfully performed.
Allogeneic transplantation
Forty-one patients underwent an allogeneic transplant. Conditioning regimens used for allogeneic transplantation were in all cases of myeloablative type according to recognized criteria, 9 the BU (16) Nine patients in first remission received a transplant from an alternative donor, in eight cases the HSC donor being a volunteer unrelated donor while in one case HSCs were obtained from an umbilical cord. Multiple HLA mismatches (X2) were present in 6/9 patients transplanted from alternative donors. GVHD prophylaxis used was standard CYA þ MTX short course, while anti-thymocyte globulin was used in volunteer unrelated donor transplants. BM was the source of HSC for most of the allogeneic transplants, and the harvest technique was optimized to yield a total nucleated cell count 43.0 Â 10 8 /kg recipient body weight in all cases of BM harvest from sibling donors. 10 Salvage treatment at relapse Nineteen patients relapsed after an autologous transplant. Treatment at relapse comprised a conventional chemotherapy schedule or high-dose chemotherapy followed by reinfusion of autologous HSC. 11 After reaching a second remission, 31% (6/19) patients who relapsed after an autologous transplant received a second transplant from an unrelated allogeneic donor.
Eleven patients relapsed before any transplant, 54% (6/11) received an allogeneic transplant in second remission.
Statistical analysis OS was measured from diagnosis to death by any cause. DFS was measured from CR to relapse or death by any cause. Cumulative incidence of relapse (CIR) was measured from CR to relapses, while patients dying from treatmentrelated mortality (TRM) were censored as a competing risk event. Cumulative incidence of TRM encompassed events occurring at any time after transplantation. OS and DFS probabilities were calculated using the Kaplan-Meier product limit; data refer to percentages at 3 years and include 95% confidence interval (95% CI). Comparison of survival times between two groups was carried out using the log rank test, whereas all three groups were compared using the trend log rank test. When log-rank was used to compare CIR between groups, deaths with no evidence of disease were censored at the time of occurrence. Categorical variable association was evaluated using the w 2 -test. Differences in continuous variables between groups were evaluated using Student's t-test or the Mann-Whitney or Wilcoxon rank sum test.
Cox proportional hazards analysis was performed after we verified that we had adequate statistical power (X10 events for each variable entered in the final model) and tested for proportionality.
NCSS 2007 software (Kaysville, UT, USA) was used for statistical calculations. A forward stepwise selection of some variables important in proportional hazards Cox model, was run using StatView software (SAS, Cary, NC, USA).
Results
Causes of deaths, relapses, OS, DFS and CIR in all cases
Overall, the OS at 3 years was 66% (95% CI, 56-77). In patients who received autologous transplantation, OS was 69% (95% CI, 52-85) with a DFS of 53% (95% CI, 37-69), whereas after allogeneic transplant OS was 74% (95% CI, 60-88) with a DFS of 70% (95% CI, 56-84). Patients who were not transplanted in first CR for any reason had an OS of 48% (95% CI, 22-75) with a DFS of 22% (95% CI, 0-43). Survival and DFS were significantly influenced by cytogenetic abnormalities present at diagnosis. In the favorable cytogenetic group, OS was 100% and DFS 81% (95% CI, 59-100); in the unfavorable cytogenetic group OS was 32% (95% CI, 0-42) and DFS 23% (95% CI, 0-45), whereas in the intermediate cytogenetic group OS was 65% (95%, CI, 53-78) and DFS 57% (95%, CI, 45-69). These differences between cytogenetic groups are statistically significant (log rank: P ¼ 0.001 for OS and P ¼ 0.009 for DFS).
Out of 96 patients, 42 had a leukemia relapse, 8/42 had an early relapse intervening within 6 months of diagnosis in patients in whom a transplant in first remission was already planned.
In all, 31 patients died, cause of death in 28 being related to relapse, while 3 patients died in first remission due to TRM. The TRM rate in first remission at any time after transplantation was 0% after autologous transplantation, 0% after allogeneic transplantation from sibling donors and 30% after allogeneic transplantation from alternative donors. When measured in patients treated by allogeneic transplants, overall cumulative incidence of TRM was 7.3% (95% CI, 2-21).
Results in patients grouped by CD34 þ peak in PB (all cytogenetic risks) Frequency of early relapses was significantly lower in patients with a peak CD34 þ cells p70 Â 10 9 /L (group A) than in patients having a peak 470 Â 10 9 /L (groups B þ C), in fact the early relapse rate was 2% in group A vs 15% in group B þ C, (P ¼ 0.01).
DFS was significantly different in groups A vs B vs C, when cases were considered irrespective of the postremission treatment administered ( Figure 1 ) and in patients who received autologous transplantation (Table 2) . After autologous transplantation, CIR was 23, 50 and 90% in groups A, B and C, respectively (P ¼ 0.0001), OS was also lower in group C (CD34 þ peak4 183 Â 10 9 /L) ( Table 2 ). In this analysis, which considered all cytogenetic risks, patients who had received an allogeneic transplantation showed no significant differences in OS, DFS or CIR in groups identified by CD34 þ cell peak in PB (Table 2) . Early relapses were significantly higher in the group having a CD34 þ cell peak above the median (470 Â 10 9 /L) than in all other patients, 15.9 vs 2.7%, P ¼ 0.04.
As observed for cases not separated according to cytogenetic risk, when we considered only intermediate risk patients, both a cut-off of 70 and 183 Â 10 9 /L identified patients with different OS, DFS and CIR. Moreover, this was found both in the group of 'all post-remission treatment' patients, and in the group of patients treated by autologous transplantation (Table 3) .
In particular, when autologous transplant patients were considered, grouping patients by CD34 þ cell peaks identified groups with a CIR of 31, 66 and 85% (P ¼ 0.015). It is noteworthy that DFS in the group (n ¼ 13) treated by autologous HSC transplantation, and having a CD34 þ cell peak in PB p70 Â 10 9 /L, was 68% (95% CI, 42-94).
The difference in DFS in groups of patients identified by CD34 þ cell level in PB was also statistically significant, when considering the intermediate cytogenetic risk patients who at diagnosis had a phenotype negative for CD34 Ag (n ¼ 24) (P ¼ 0.008). In the same way, the prognostic influence on DFS by grouping patients based on CD34 þ cell peak was also evident, when only the patients with a normal cytogenetic karyotype were considered (n ¼ 54), P ¼ 0.001.
In the intermediate cytogenetic risk patients treated by allogeneic transplantation (n ¼ 33), the group of patients with a CD34 þ cell peak above 183 Â 10 9 /L (n ¼ 8) had an OS and DFS significantly lower, and a CIR higher than patients with a CD34 þ cell peak below 183 Â 10 9 /L (n ¼ 25) (Figure 2 ). In fact, OS was 91% (95% CI, 79-100) vs 50% (95% CI, 15-84) (P ¼ 0.001) and DFS was 88% (95% CI, 74-100) vs 50% (95% CI, 15-84) (P ¼ 0.009), in patients with a CD34 þ cell peak below 183 Â 10 9 /L and in patients with a CD34 þ cell peak above 183 Â 10 9 /L, respectively. Finally, groups identified by a CD34 þ cell peak in PB above and below 183 Â 10 9 /L had different prognoses, even when only patients transplanted from an HLA identical sibling were considered (n ¼ 27). In this group, in fact, patients had a CIR of 9% (95% CI, 2-40) vs 60% (95% CI, 30-100) (P ¼ 0.002) and a DFS of 90% (95% CI, 78-100) vs 40% (95% CI, 0-82) (P ¼ 0.002), in the groups with a CD34 þ cell peak op183 (n ¼ 22) and in the group with CD34 þ cell peak 4183 Â 10 9 /L (n ¼ 5).
Correlation among peak of CD34 þ cells in PB, infused CD34 þ cells and harvested CD34 þ cells and selection of variables important with respect to DFS Seventy patients underwent PBSC harvest by apheresis. The median number of CD34 þ cells in first apheresis was 6.95 Â 10 6 /kg (range 0.7-32.1). There was correlation, as could be expected, between the peak of CD34 þ cells in PB ( Â 10 9 /L) and harvested CD34 þ cells ( Â 10 6 /kg) (R ¼ 0.77, P ¼ 0.0001). Twenty-two patients were treated by auto-SCT in 1st CR using PBSC as HSC source, mean number of CD34 þ infused was 6.2 Â 10 6 /kg (range 2.8-11.3). Between the variables peak of CD34 þ cells in In a univariate analysis of DFS, infused CD34 þ cells had a risk ratio (RR) of 1.170 (P ¼ 0.03), peak of CD34 þ cells in PB had a RR of 1.001 (P ¼ 0.0007) and harvested CD34 þ cells had a RR of 1.041 (P ¼ 0.04). To select the variables important in a multivariate analysis, these three were entered in a Cox regression multivariate analysis in stepwise selection mode. Only the CD34 þ cell peak in PB was retained in the model (P to remove ¼ 0.004) and not infused CD34 þ cells (P to enter ¼ 0.64) or harvested CD34 þ cells (P to enter ¼ 0.96). Therefore, in the ensuing multivariate analysis peak of CD34 þ cells in PB was chosen as the CD34-related factor to be evaluated.
Evaluation of factors important for DFS in all cases (univariate and multivariate analysis)
In univariate analysis, WBC at start of treatment (P ¼ 0.62) and CD34 þ phenotype in leukemic cells (P ¼ 0.26) were found not to be important for DFS. Variables that had a Pp0.1 were:
Age at diagnosis evaluated as continuous variable: RR ¼ 1.022 (P ¼ 0.10).
Peak of CD34 þ cells in PB, as a continuous variable: RR ¼ 1.001 (P ¼ 0.0007).
FAB classification in two classes FAB M4-M5 vs M0-M1-M2 (reference group): RR ¼ 0.494 (P ¼ 0.03).
Cytogenetic risk group, in three classes: favorable (reference group); intermediate: RR ¼ 3.083 (P ¼ 0.12); unfavorable: RR ¼ 7.397 (P ¼ 0.01).
When all of these variables were evaluated by multivariate analysis using a Cox proportional hazards model, only peak of CD34 þ cells in PB maintained its significance with a RR of 1.001 (P ¼ 0.0009).
The results did not change substantially if cumulative incidence of relapse was considered instead of DFS.
Evaluation of factors important for DFS in stratum of intermediate risk cytogenetic (univariate and multivariate analysis)
As the majority of FLT3-ITD studied patients belonged to the intermediate cytogenetic risk group and as the prog- Table 2 Outcome according to CD34+cell peak and to post-remission treatments (all cytogenetics groups) (reference group) with a RR of 0.502 (P ¼ 0.10), FLT3-ITD ( þ ) vs FLT3-ITD (À) (reference group) with a RR of 2.233 (P ¼ 0.08), and peak of CD34 þ cells in PB, as a continuous variable, with a RR of 1.001 (P ¼ 0.0001). When all these factors were considered in a multivariate analysis, only peak of CD34 þ cells in PB retained significance with a RR of 1.001 (P ¼ 0.003).
Discussion
Previously published data have already shown that, in AML patients, a high CD34 þ cell content in apheretic harvest is negatively correlated with prognosis.
1,2 A large quantity of CD34 þ cells in the inoculum infused during autologous transplantation has also been shown to predict a higher risk of relapse. 12 As a large number of harvested CD34 þ cells are associated with a large number of infused CD34 þ cells, the latter have been considered to be the real cause of the increased risk of relapse.
However, our study shows that an increased CD34 þ cell value in PB mobilization is negatively correlated with prognosis not only in patients who are re-infused during autologous transplantation, but also in patients treated by allogeneic transplantation or not transplanted at all. Thus, the prognostic value of the degree of mobilization is a biological marker of poor prognosis independent of the amount of CD34 þ cells re-infused.
Peak of CD34 þ cells in PB and not infused CD34 þ cells, was more important to DFS in our multivariate analysis. The fact that we chose a parameter reflecting the degree of mobilization more precisely than the number of infused CD34 þ cells, allowed us to better predict DFS in spite of the relatively small number of patients. In fact, it has been previously reported that dividing the cases by the number of CD34 þ infused, allowed for the detection of a 15% difference in DFS between groups having different numbers of infused CD34 þ cells after autologous transplantation. 12 However, the use of the CD34 þ cell peak as a means to divide patients allowed us to identify groups with a much greater difference in terms of DFS.
The main finding of our study was the identification of a subgroup of cytogenetic intermediate risk patients that consisted of approximately 25% of patients who reached CR and showed a CD34 þ cell peak 4183 Â 10 9 /L, and a high risk of relapse after the first consolidation course. We also found that within this group, those who had a CD34 þ cell peak o70 Â 10 9 /L after auto-SCT had notably good results, with a DFS 465%.
However, our suggestion that the measurement of CD34 þ cell mobilization is useful in predicting the prognosis of cytogenetic intermediate risk patients must be validated.
CD34 þ cell mobilization patterns may be influenced by infections during the aplastic phase, and by administration during the consolidation cycle of chemotherapy drugs different from those utilized in this study, suggesting possible pitfalls in using CD34 þ cell mobilization as a marker for prognosis in AML.
In order to confirm the value of CD34 cell mobilization, the peak of CD34 þ cells in PB can be measured in patients after they receive consolidation chemotherapy in a G-CSF trial. In AML patients, administration of G-CSF after consolidation chemotherapy is recommended by American Society of Clinical Oncology (ASCO) and British Society for Clinical Haematology (BSCH) guidelines.
The mobilization and harvesting of PBSC is a useful clinical procedure in patients selected to receive an allogeneic transplantation, as an autologous back up may be needed in case of graft rejection. 13 Therefore, we recommend obtaining the measurement of the CD34 þ cell peak in PB in all AML patients during the first remission.
By using auto-SCT we obtained in the cytogenetic intermediate risk group an OS of 61% with a DFS of 48%. These results are comparable with those recently published, where auto-SCT was used with an OS of 56% 14 and a DFS of 53% in an intermediate group of patients below the age of 60. 15 An OS of 62% and a DFS of 56% have been reported in a retrospective multicenter series of 129 patients treated by auto-SCT. 16 These results do not support the reduced rate of auto-SCT as a post-remission treatment of AML observed in recent years. We believe that two key points have a role in achieving better results with auto-SCT, correct identification of patients who can be cured by auto-SCT and optimization of the harvesting technique.
Promising results have been reported on treatment with auto-SCT of intermediate risk patients having low levels of minimal residual disease as measured by leukemia-associated immunophenotype. 17 Good cytogenetic risk patients can also have excellent results after auto-SCT. 18 Based on our work, the pattern of CD34 þ cell mobilization could CD34 peak in AML G Milone et al also be useful in selecting the patients for auto-SCT. However, a direct comparison of the value of these different assays is needed, as well as determining their reproducibility in different clinical settings. As well as correctly identifying patients who would benefit most from auto-SCT, we believe that our data highlight the importance of optimizing the harvesting of HSCs in AML patients treated by auto-SCT.
In fact, we showed that better results after auto-SCT can be obtained in 'poor mobilizer' AML patients in whom the harvest is difficult and that, in contrast, patients with easy harvests have poor DFS after auto-SCT. Thus, it is important to optimize the harvesting so that poor mobilizers are not excluded from receiving auto-SCT only because it is difficult to obtain enough cells in these patients. The cellularity of a marrow harvest also has a prognostic significance and richer marrows have been linked to a higher incidence of relapse after auto-SCT. 19 In light of these considerations, we question whether harvesting by apheresis or from BM in AML patients should be carefully planned and performed in an experienced center to prevent selection bias.
In our hands, allogeneic transplantation from sibling donors gave results comparable with those obtained in recent wider studies, 20, 21 confirming that AML patients in the 1st CR aged below 60 have a risk of TRM below 10%. Therefore, we believe that allogeneic transplant is the treatment of choice in patients with a greater than 20% risk for relapse and a suitable sibling donor, and that delaying the treatment in case of a relapse would not be the best choice. This low TRM contrasts with conclusions drawn from multicenter studies, in which a TRM as high as 21% has been reported in the donor arm of a study employing allogeneic transplants. 22 In our experience, the main problem after allogeneic transplants from sibling donors in 1st remission AML patients remains relapse of the disease. Identification of patients at risk of either early relapse before transplant or at risk of relapsing after transplant would improve results of allogeneic transplantation from sibling donors. If correctively identified these patients could receive an intensification of conditioning or modulation of immunosuppressive treatment. The prognostic value of CD34 þ cell mobilization in the cytogenetic intermediate risk group treated by allogeneic transplantation should be prospectively confirmed and compared with other tests, such as WT1 expression, that have been proposed to identify patients at risk of relapse after allogeneic transplantation. 23 Molecular markers have been proposed to guide postremission decisions in cytogenetic intermediate risk patients with no sibling donor. The use of an allogeneic transplant from an alternate donor during the first remission in patients in the cytogenetic intermediate risk group, has been recommended for those with mutated FLT3. 24 In the limited number of patients who we have studied, the group with high CD34 þ cell mobilization efficacy and a poor prognosis did not have an increased proportion of FLT3-ITD mutated patients, and in our multivariate analysis the CD34 þ cell peak was an independent prognostic factor from the FLT3 status. However, further study is needed to clarify whether the super mobilization pattern is linked to any other molecular abnormality known to have a negative prognostic value in intermediate risk patients, such as EVI-1, BAALC, or c-kit mutation. 25 The reasons for the association between high CD34 þ cell count and an increased rate of relapse in AML have not yet been established. We believe that a high peak of CD34 þ cells is associated with a high level of minimal residual disease (MRD), but this does not mean that the bulk of CD34 þ cells mobilized in PB are leukemic cells. Instead, we believe that the bulk of these cells are nonleukemic CD34 þ cells for various reasons. First, Keating studied MRD in CD34 harvests and found a high percentage of MRD in patients having a richer harvest. However, the level of MRD in the apheretic product was on the order of 8%, 1 which could not explain the amount of CD34 þ cells harvested. Instead, non-leukemic CD34 þ cells accounted for 90% of the total amount of CD34 þ cells harvested.
Second, in super mobilizer patients we have studied MRD using FLT3-ITD as a leukemic marker in clonogenic cells grown in vitro from marrow cells obtained in the 1st CR at the time of mobilization. We found that all the clones of CFU-GM obtained from the marrow of these patients at the time of mobilization, were composed of non-leukemic cells (unpublished data).
A possible explanation for the association between high CD34 þ cell count and an increased rate of relapse is that super mobilizing patients have different pharmacokinetics with respect to all other patients, and that this difference results in reduced clearance of leukemia cells and reduced myelotoxicity for non-leukemic cells, causing an increase in mobilizing capacity. 1, 2 We have studied the chemosensitivity of clonogenic marrow precursors obtained from marrow 3 weeks after CD34 þ cell mobilization in a group of 50 patients. In super mobilizing patients we observed an increase in the chemoresistance of the marrow hematopoietic clonogenic precursors obtained from CR patients. 26 Interestingly, this increase in in vitro chemoresistance of the clonogenic precursors found in some AML patients correlated not only to a high mobilization of CD34 þ cells but also with decreased DFS. Our findings suggest that abnormal behavior of normal non-leukemic marrow precursors cells causes CD34 þ super mobilization.
Indeed, in a subsequent study carried out in AML CD34 þ super-mobilizing patients, we found that nonleukemic CD34 þ cells obtained in CR have a distinctive genomic expression profile, with higher expression of antiapoptotic genes compared with patients with a lower degree of CD34 þ cell mobilization. 27 Measuring HSC chemoresistance or HSC anti-apoptotic gene expression may help to predict DFS.
The association between features pertinent to leukemic cells, such as increased leukemic aggressiveness, and features belonging to normal HSCs, such as increased CD34 þ cell mobilization ability, remain to be explained. We hypothesize that the higher CD34 þ cell mobilization, we have found, in some AML patients could be due to some leukemic cells having a greater ability to interact with and activate the hematopoietic microenvironment niche, in an amount compatible with MRD. As a consequence of this variable niche activation, a higher chemoprotection could be induced in some patients at the same time toward residual leukemic cells 28 (thus explaining the higher level of MRD and lower DFS) and toward normal HSC (thus explaining high CD34 þ cell mobilization ability). This hypothesis could also explain the fact that super mobilizing patients have shorter aplastic phases after consolidation cycles. 2, 26 It can also be expected that this function of some leukemia cells will be associated and dependent on other known molecular malignancy markers.
In conclusion, we have shown that the CD34 þ cell peak in PB obtained after a first consolidation cycle can identify a subset of patients within the intermediate cytogenetic risk group that have a poor prognosis due to high rates of relapse after autologous transplantation and also, to a lesser extent, after allogeneic transplants.
